LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

10.2 -2.3

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.15

Max

10.54

Belangrijke statistieken
By Trading Economics
Inkomsten	-8M -74M
Verkoop	5.5M 21M
EPS	-0.85
Winstmarge	-357.186
Werknemers	192
EBITDA	-1.3M -74M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+170.02% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	165M 1B
Vorige openingsprijs	12.5
Vorige sluitingsprijs	10.2

Nieuwssentiment

By Acuity

19%

81%

42 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

5.575 / 6.6 Steun & Weerstand

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2025, 23:58 UTC

Acquisities, Fusies, Overnames

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dec 2025, 23:56 UTC

Winsten

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Winsten

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dec 2025, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 dec 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dec 2025, 23:37 UTC

Marktinformatie

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dec 2025, 23:31 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 22:48 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:35 UTC

Winsten

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dec 2025, 22:30 UTC

Winsten

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dec 2025, 22:05 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 21:51 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

11 dec 2025, 21:39 UTC

Winsten

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dec 2025, 21:39 UTC

Winsten

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dec 2025, 21:38 UTC

Winsten

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dec 2025, 21:37 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dec 2025, 21:37 UTC

Marktinformatie

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dec 2025, 21:34 UTC

Acquisities, Fusies, Overnames

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dec 2025, 21:28 UTC

Marktinformatie

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus: Third Party Investors to Contribute Remainder

11 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dec 2025, 21:25 UTC

Acquisities, Fusies, Overnames

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

170.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29 USD 170.02%

Hoogste 40 USD

Laagste 16 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

42 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.